Che-Yu Hsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Che-Yu Hsu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chih-Ho Lai
Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, Chang Gung University
1 shared publication - Chun-Lung Feng
Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung 404332, Taiwan
1 shared publication - Pei-Yi Chu
Department of Pharmacy, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan
1 shared publication - Po-Hung Hsu
Center for Advanced Molecular Imaging and Translation, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
1 shared publication - Shin-Lei Peng
Department of Biomedical Imaging and Radiological Science China Medical University Taichung Taiwan
1 shared publication - Wen-Ying Huang
Department of Applied Cosmetology, Hung-Kuang University, Taichung 433304, Taiwan
1 shared publication
Latest Publications
- Open Access
- 25 August 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (9) , 1327
Targeting Tumor Cells with Nanoparticles for Enhanced Co-Drug Delivery in Cancer Treatment
Gastric cancer (GC) is a fatal malignant tumor, and effective therapies to attenuate its progression are lacking. Nanoparticle (NP)-based solutions may enable the design of novel treatments to eliminate GC. Refined, receptor-targetable NPs can selectively target cancer cells and improve the cellular uptake of drugs. To overcome the current limitations and enhance the therapeutic effects, epigallocatechin-3-gallate (EGCG) and low-concentration doxorubicin (DX) were encapsulated in fucoidan and d-alpha-tocopherylpoly (ethylene glycol) succinate-conjugated hyaluronic acid-based NPs for targeting P-selectin-and cluster of differentiation (CD)44-expressing gastric tumors. The EGCG/DX-loaded NPs bound to GC cells and released bioactive combination drugs, demonstrating better anti-cancer effects than the EGCG/DX combination solution. In vivo assays in an orthotopic gastric tumor mouse model showed that the EGCG/DX-loaded NPs significantly increased the activity of gastric tumors without inducing organ injury. Overall, our EGCG/DX-NP system exerted a beneficial effect on GC treatment and may facilitate the development of nanomedicine-based combination chemotherapy against GC in the future.
- 25 August 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (9) , 1327
Open AccessTargeting Tumor Cells with Nanoparticles for Enhanced Co-Drug Delivery in Cancer Treatment
Gastric cancer (GC) is a fatal malignant tumor, and effective therapies to attenuate its progression are lacking. Nanoparticle (NP)-based solutions may enable the design of novel treatments to eliminate GC. Refined, receptor-targetable NPs can selectively target cancer cells and improve the cellular uptake of drugs. To overcome the current limitations and enhance the therapeutic effects, epigallocatechin-3-gallate (EGCG) and low-concentration doxorubicin (DX) were encapsulated in fucoidan and d-alpha-tocopherylpoly (ethylene glycol) succinate-conjugated hyaluronic acid-based NPs for targeting P-selectin-and cluster of differentiation (CD)44-expressing gastric tumors. The EGCG/DX-loaded NPs bound to GC cells and released bioactive combination drugs, demonstrating better anti-cancer effects than the EGCG/DX combination solution. In vivo assays in an orthotopic gastric tumor mouse model showed that the EGCG/DX-loaded NPs significantly increased the activity of gastric tumors without inducing organ injury. Overall, our EGCG/DX-NP system exerted a beneficial effect on GC treatment and may facilitate the development of nanomedicine-based combination chemotherapy against GC in the future.